Important Note: This site is designed to work best in Firefox, Safari or Chrome. Please update your browser to view the complete site.


How to Reduce Gut Activity with Myocardial Perfusion Imaging

Posted on: 11.15.18

We’re all familiar with the obstacles that radiotracers and subsequent gut activity presents during Myocardial Prefusion Imaging. When the radioisotope expands beyond the coronary arteries, it’s difficult to obtain quality SPECT MPI imaging of the heart. It’s a common problem that plagues many patients and physicians. So what do we do?

We’ve heard of everything from half & half, cold water, and even a certain type of soda post injection to reduce the dreaded gut activity. Since we weren’t aware of any tried and true solution, we polled our fellow nuclear specialists on LinkedIn to see if they could provide some tips, tricks and home remedies.

Wait Time is always going to be your best practice to assist with clearance but if that or your go-to response doesn’t always work, check out these suggestions and add them to your list:

Katrina B.
If it is a bowel loop, we give them another cup of cold water and have them walk the hallway if they can. If they have a hiatal hernia or liver disease, we give them a longer wait time prior to scan to try to avoid the need for rescan. And we ask them all not to lay down, but to sit up instead when possible when waiting.

Rhevon L.
In my experience, the most effective method for reducing gut uptake and obtaining separation from the inferior margin is the combination of walking and ice cold water consumption. I have also heard of technologist giving patient’s Boost/Ensure after rest dosing and obtaining great images. This is done at the discretion of exercise stress, however.

Kim L.
Additional cold water – approximately 8 ounces. Drink fast. Walk around for 5-10 minutes, then have the patient lay on their right side to see if the loop will pull away from the bottom half of the heart. I had a tech that worked for me that came from Ohio State, and they would try this. Sometimes it would work and sometimes it wouldn’t. Always feed them. That, of course, helps for most.

Michael B.
We find that waiting is the best remedy but not always practical. Cold water gulped down for resting scan. Snack and a drink for the stress scan. Sometimes, particularly with hot livers, lying the patient on 2 pillows behind the shoulders, raising them will drop the activity away from the heart.

Neda S.
I have used carbonated sodas if walking and drinking water didn’t help. I used to use Diet Sprite, but I guess ginger ale is an option too. For stress images, fatty foods, ice cream, coffee, anything that helps bowel movement.

Patrick B.
I’ve often placed a broad strip of pliable soft lead shielding over the patient’s abdomen at an angle, and this has often helped mitigate proximal intestinal activity. Otherwise, if you have the time, waiting 45-60 minutes post-injection to perform resting MPI has been fairly beneficial.

Jeremy W.
I like for my patients to have a drink of their choice (soda, water, coffee, etc.) and some crackers or small snack before their stress images. Some water only before rest images. Extra wait time for Cardiolite vs. Myoview, especially for liver clearance.

What is the Role of Cardiac Cath in Value-Based Care?

Posted on: 10.04.18

It’s an undeniable fact that the move to value-based care is changing cardiology. Cardiac catheterization, in particular, has evolved as appropriate use criteria and value-based care have continued to advance in the healthcare system.

This once go-to procedure is now being replaced by new methods and less invasive techniques. In this post, we’ll take a look at where cardiac cath fits in today’s value-based landscape.

How we got here

Years ago it was common for the cath lab to be the first stop for patients experiencing symptoms of cardiovascular disease. It was a valuable diagnostic procedure with solid reimbursements and relatively little oversight from payers. Today, the rules have changed.

In many ways, the cardiac cath landscape changed after the American College of Cardiology published the 2009 AUC for Coronary Revascularization.

As Medicare and CMS developed their guidelines, the criteria became more and more a part of the cardiology landscape. Additionally, the way payers approach cardiac catheterization has continued to evolve. Increased scrutiny is being added to the procedure while reimbursement rates continue to decline.

Lately, these factors have been compounded as significant penalties for patient readmission and not following AUC have been added.

The move to non-invasive techniques

It’s said that necessity is the mother of invention, and this has held true for how cardiologists are approaching cardiac catheterization in the current market.

We are seeing a rise of new non-invasive diagnostic tools as a way to mitigate lower reimbursements, penalties, and improve patient care.

Cath is still an essential tool for both patients and cardiologists, but now physicians are wanting more evidence and clarity before ordering the test. Non-invasively obtaining proof that disease exists has now become step one in the process.

The impetus behind these changes makes sense on a number of levels. The net result of doing more tests before the cath lab is that cardiologists are performing fewer invasive and unnecessary procedures. This is good for the patients and the healthcare system as a whole. While a reduced study volume does affect the bottom line, it is also resulting in the practice experiencing lower readmission fees and penalties for not following AUC.

Non-invasive methods gaining traction

Fractional Flow Reserve

Many cardiologists are choosing to utilize fractional flow reserve, or FFR, as a way to diagnose heart disease and guide clinical management. It non-invasively measures the difference between the maximum achievable blood flow in the presence of stenosis and the theoretical normal maximum blood flow in terms of pressure using coronary artery images.

FFR simulation is able to more accurately identify those patients who have a high likelihood of disease. So, not only does the method comply with the stricter enforcement of AUC, but it has also improved the percentage of catheterizations that ultimately result in an intervention.

Advances in SPECT

Nuclear SPECT studies play a vital role in the diagnosis of cardiovascular disease. The nature of SPECT makes it a perfect fit for value-based care, but too often the clinical value of SPECT depended on the reader.

New advances in SPECT imaging are bringing Attenuation Correction into this modality. The addition of Attenuation Correction is making images clearer and easier to read.

The studies and the cameras, such as the Digirad X-ACT+, are considerably more affordable compared to traditional CT imaging. This creates a tremendous amount of value – both clinically and for the healthcare system.

Cardiac PET

As imaging technology continues to advance, Cardiac PET MPI is gaining more awareness in today’s clinical market. In recent years, the modality has seen growth and is generating interest among cardiologists.

While the diagnostic benefits of Cardiac PET are clear, the cost and complexity of offering the modality have kept it from being a realistic option for most practices.

Medical Therapy

It’s also important to consider how medical therapy is changing cardiology. Research has shown that moving straight to medication as opposed to investing in diagnostic procedures is an effective way to treat patients.

The Bottom Line on Cardiac Catheterization

Cardiac Catheterization and Percutaneous Coronary Intervention will obviously continue to play a vital role in cardiology. As technology continues to advance, non-invasive methods will become more effective and more affordable.

As an industry, we may continue to see fewer cath tests ordered but they will be ordered with more clinical confidence. In the end, these changes benefit the patient while also reducing the financial risk to the practice and the healthcare industry as a whole.

This post was written in partnership with MedAxiom and includes contributions from Jacob Turmell DNP, RN, NP-C, ACNS-BC, CCRN-CMC and Joel Sauer.

A Closer Look at the Digirad Ergo (Infographic)

Posted on: 08.23.18

Download a PDF version of this infographic

Understanding Your Nuclear Medicine Stress Test

Posted on: 06.21.18

Myocardial Perfusion Imaging, also called a Nuclear Stress Test, is used to assess coronary artery disease, or CAD. CAD is the narrowing of arteries to the heart by the build up of fatty materials.

CAD may prevent the heart muscle from receiving adequate blood supply during stress or periods of exercise. This frequently results in chest pain, which is called angina pectoris. Perfusion imaging usually consists of stress and rest tests.

Images are taken of your heart while at rest and after exercising or under stress. The comparison allows your physician to evaluate blood flow under different levels of exertion. After the images are reviewed, they’ll meet with you to discuss the results.

Understanding Your Nuclear Medicine Stress Test

Normal or abnormal, what does it mean?

A normal test result indicates there is sufficient and unrestricted blood flow to your heart, both during periods of rest and exercise. Generally, there’s little concern for coronary artery disease and, in most cases, you won’t require any further testing.

An abnormal result, which means your heart’s blood flow is insufficient, may occur only during the exercise phase of your stress test. During rest, your blood flow may be normal, but during strenuous activity, when your heart is working harder, it may not be getting the blood supply it needs. It’s likely that there is some level of coronary artery disease or blockage.

An abnormal result in both phases of your stress test is an indication that your heart’s blood flow is poor, regardless of your exertion level. The restricted blood flow suggests significant coronary artery disease. If your stress test images show areas of the heart that are not highlighted with the radioactive isotope, it may also be an indication of scar or damaged tissue caused by a previous heart attack.

Regardless of the results, your doctor will explain the findings and address your concerns. If necessary, they’ll recommend a treatment plan that can potentially improve or better manage your heart’s function.

Seven mistakes to avoid when choosing between a new and refurbished nuclear camera

Posted on: 04.26.18

With the continual advancements in healthcare technology and service, investing in your cardiac practice, upgrading equipment, and improving efficiency is an ongoing process. One of the most significant considerations is not only when to replace a camera, but also if refurbished, or new equipment might be a better decision.

It’s important to take the time to look beyond your immediate imaging needs and consider the long-term goals of your practice. Both refurbished and new camera systems come with advantages, but be sure to consider these factors before signing on the dotted line:

1. Focusing only on purchase price vs. the long-term cost of ownership

A nuclear gamma camera is a significant investment for any practice, so it’s natural to focus on the cost. There are times when prioritizing price is a smart idea, but only when the product still retains an acceptable level of value. There are many refurbished cameras that have a considerable amount of life left and could be a wise investment.

When you evaluate new versus used equipment, consider how much image quality has improved in recent years, the availability of new software programs, and the viability of the camera’s current operating system. When the camera is in need of repair, will parts be readily available and will the manufacturer agree to service it? Some manufacturers include a firm end-of-service date on their equipment, which leaves you at the mercy of third-party service providers and replacement parts. Some service companies may even decline service because of age, limited part availability, and the associated risk.

2. Overlooking the ability to maintain image quality

Older, refurbished cameras may undoubtedly be in working order, but their boards and analog methodologies could be less effective. With age, the camera’s light pipe, which includes crystals that eventually yellow and crack, will no longer respond, sometimes without warning. Replacement crystals for older cameras may not be available. Even with newer refurbished cameras, the crystals have already aged, may be hydrated, and are potentially unfixable. Be sure to inquire about and examine the crystals if you’ve considering a refurbished camera.

3. Putting your HIPAA compliance at risk

Another important factor to consider is HIPAA compliance. Many refurbished cameras cannot be upgraded to current software versions, and, because they’re no longer supported by the manufacturer, they can’t they be patched securely. Consequently, the camera cannot be connected to a network because internet access imposes new risks. You also may not be able to add additional processing programs and, in the end, may be forced to purchase an entirely new software package, which will be costly.

4. Not factoring in the credit rating of the practice

While many physicians may have excellent credit, they may not be willing to put their personal credit history on the line when purchasing capital equipment such as a nuclear gamma camera. Instead, they opt to leverage the business credit, and this can have a direct impact on the approval process and interest rate.

If the practice does not have an extensive credit history, it’s more challenging to secure a loan, and interest rates are likely higher on pre-owned equipment. Additionally, if a financial institution feels that you may have issues with part availability on refurbished systems, they may be hesitant to approve a loan for older medical equipment. Be sure to discuss the details and get loan pre-approval before the sales process begins.

5. Failing to consider the true patient volume

Volume is another important factor to evaluate when deciding between used or new equipment-or even whether to outsource your imaging services completely. Not all cardiac practices need a camera on site five days a week. If you’re imaging one, two, or even three days a week, you might consider partnering with a mobile imaging company.

Your volume should factor into your financial investment. Without it, the lack of revenue wouldn’t warrant spending dollars on maintenance costs and might eventually lead to a decline in the integrity of the equipment.

6. Purchasing camera that offers limited use

Any new or used camera that you plan to purchase should be able to expand and grow with your practice. A camera should be able to fill your current imaging needs, but also serve your practice in other ways. Would it lend itself to increased productivity, improved efficiency, and greater patient satisfaction? Sometimes it may be worth the extra investment if it allows you to move forward on another strategy that has the potential to increase revenue or to reach other goals.

7. Not performing your own due diligence

Lastly, knowing from whom you’re purchasing your equipment is of critical importance. An investment of this size should only be made through a reputable company with a proven track record, especially if it’s a refurbished camera. Prepare a due diligence checklist and take the time to get better acquainted with the camera, just as you would with a home, used car, or any other purchase in the second-hand market. Ask to see it, or have it inspected by an independent service company, and ask for the repair and maintenance records.

It’s well within your rights to investigate the camera’s history, current value, and the likelihood of any future issues before making a final commitment. If you don’t, you’re exponentially increasing your chance of winding up with a lemon and having no recourse.

Cost shouldn’t be the only consideration when buying a camera. It may be high on your list, but the value it brings to your practice should be well worth the money you spend.

PET/CT Imaging New Tracer Guide

Posted on: 03.30.18

The landscape of PET/CT imaging is rapidly changing. Traditionally, physicians have used a sugar based radiopharmaceutical, 18Fluorodeoxyglucose or 18FDG, to perform the majority of PET/CT imaging. Over the past 20 years, this imaging agent was the only option available to many facilities across the United States.

Recent breakthroughs in research, reimbursement, and radiopharmaceutical manufacturing have made it so that physicians and patients will begin to have access to medicine that is designed for their unique situations.


Prostate Cancer


Axumin (18F-Fluciclovine) is indicated for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

Mechanism of localization

It has been found that there is an over expression of amino acid transporters in certain cancer cells. This overabundance of amino acid transporters is typically easier to identify among normal, healthy tissue than traditional imaging methods. The body recognizes this drug as an amino acid and actively transports it to potential areas of concern.

Why look into this radiopharmaceutical?

  • Axumin allows healthcare providers to pinpoint the overexpression of amino acids associated with prostate cancer.
  • Increased visualization of the prostate bed— no bladder interference during imaging, as with traditional 18FDG.
  • PET imaging with Axumin can lead to quicker detectionof tumors. Other imaging methods rely on physical (structural) changes in the body for tumor detection, whereas Axumin detects changes on the physiological (cellular) level, which can occur weeks, even months quicker than physical changes.

Prescribing information and use

  • A standard 10 mCi dose of 18F-Fluciclovine is provided
  • Patient is injected and imaged immediately
  • Exam takes less than 30 minutes from start to finish

Axumin is a great tool for visualizing the prostate bed which can be challenging using traditional methods.


Neuroendocrine Tumors


NETSPOT (68Ga-Dotatate) is indicated for use withPET for localization of somatostatin neureceptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.

Mechanism of localization

68Ga-Dotatate binds to somatostatin receptors, with highest affinity for subtype 2 receptors (sstr2). It binds to cells that express somatostatin receptors including malignant cells, which overexpress sstr2 receptors.

Why look into this radiopharmaceutical?

Improved image quality over the traditional Gold Standard

The Gold Standard method of imaging NETs has traditionally been an Octreotide scan

  • Often times leaves physicians without answers
  • Takes up to a week to acquire the entire exam
  • Results are only qualitative

NETSPOT imaging

  • Results are conclusive
  • Improved patient satisfaction: no bowel prep needed or dietary restrictions, 3 hours to complete examination
  • Results are quantitative and qualitative

The FDA has recently approved a therapy for NETs that uses the same Dotatate as the PET imaging agent and replaces the 68Ga with 177Lu. The theranostic (see it,  treat it) approach to treatment has finally become a reality!

Prescribing information and use

  • A patient specific, weight based dose of 68Ga- Dotatate is provided
  • Patient is injected and imaged at 40-90 minutes post administration
  • Must be off somatostatin receptor blocking agents

Same Patient— Different Outcome

A) Standard imaging using Octreotide

B) Improved tumor visualization and treatment planning using 68Ga-Dotatate


Alzheimer’s Disease


  • Adults with cognitive impairment who are being evaluated for Alzheimer’s disease and other possible causes of cognitive decline
  • Currently 3 approved PET/CT imaging agents areavailable: Neuraceq (18F-Florbetaben), Amyvid (18F-Florbetapir), Vizamyl (18F-Flutemetamol)

Mechanism of localization

  • There are many studies that demonstrate a relationship between increased β-amyloid plaque and Alzheimer’s disease.
  • The radiopharmaceuticals bind to this β-amyloid plaque.

Why look into this radiopharmaceutical?

  • Until recently, there was no way to image the presence of the physiological changes associated with Alzheimer’s disease:
  • A positive scan indicates an increase β-amyloid plaque which is consistent with AD and other cognitive disorders: To be used in conjunction with other neurological testing to establish a diagnosis
  • A negative scan indicates that there is a low amountof β- amyloid plaque which is inconsistent with a neuropathological diagnosis of AD
  • Helps to rule out the possibility of AD

Prescribing information and use

  • Each radiopharmaceutical has its own prescribing and dosing information
  • Patient is injected and imaged
  • Entire exam takes less than 90 minutes from start to finish





  • Cancer—most common
  • Infection & inflammation
  • Viable myocardium (cardiac)
  • Brain – seizure, epilepsy, Alzheimer’s disease, dementia, tumors

Mechanism of localization

18Fluorodeoxyglucose (18FDG) is a sugar molecule that concentrates in areas of high glucose metabolism. Healthcare providers are seeking to determine whether there is an abnormal amount of uptake of this tracer in a particular area of the body which may be indicative of a particular health concern.

Why look into this radiopharmaceutical?

This is the most widely used imaging agent in the world of oncology. Many referring physicians are familiar with this drug and its applications for oncologic purposes. It is generally accepted as the drug to use for most cancers.

Many physicians and facilities are not familiar with the other indications and usages of this imaging agent. Examples include: Viable myocardium—this drug can be used to determine what sections of the heart are still viable and have living, functioning cells.

Brain – Many times, 18FDG can add valuable information that a neurosurgeon needs prior to surgery. Functional changes occur much earlier than physical changes—PET/CT images often compliment CT or MRI images.




This radiopharmaceutical is most commonly used to identify cancers of the bone or cancers that have metastasized (spread) into the bone. The Sodium 18Fluoride (NaF18) ions are deposited directly into the bone matrix and bone surface. Common sites are newly mineralized bone, such as during growth, infection, malignancy (primary or secondary), after trauma, or during inflammation.

Why look into this radiopharmaceutical?

This drug is much better at targeting skeletal activity than FDG and provides a much clearer image than traditional nuclear medicine bone scans. These 3D images are also quantitative which allows physicians to precisely measure the activity within a lesion – allows for a more accurate interpretation of the response to treatment.

Prescribing information and use

  • The imaging agent is ordered and delivered for each specific patient
  • There is no patient prep
  • Patient is injected and imaged
  • Entire exam takes roughly 90-120 minutes

Intraoperative benefits of Ergo touted in the Journal of Pediatric Surgery

Posted on: 03.15.18

The portability of the Digirad Ergo Imaging System is making a significant impact in the pediatric oncology world. The Journal of Pediatric Surgery recently published an article on its intraoperative use. Most notably, it reported on how nuclear imaging with the Ergo effectively reduces the time under anesthesia and offers real-time confirmation of lesion removal. Digirad recently spoke with Dr. Marcus M. Malek of Children’s Hospital of Pittsburgh of UPMC, to further elaborate on the study.

Single environment reduces time under anesthesia

In order to guide lymph node biopsy, pre-surgery lymphatic mapping is done via lymphoscintigraphy. Adults and teens are generally able to tolerate the procedure while awake. It does, however, involve an injection and the need to remain still, which can often be difficult for a child. For that reason, young pediatric patients, and some adults for that matter, are sedated and mapped in the nuclear medicine suite and then transported to the operating room. The additional step takes a considerable amount of time and coordination, which leads to downtime in the OR.

The portability of the Digirad Ergo allows the patient to be anesthetized while they’re in the operating room. Prior to the start of the surgery, the nuclear medicine technologist or physician injects the radiotracer in standard fashion. After the tracer has moved to the area of interest, the Ergo acquires the images needed for the lymphoscintgraphy. Once the sentinel nodes are marked and the area is prepped, the surgery can begin without delay. When the procedure and the surgery are done in one environment, it’s safer for the patient, spares them additional time under anesthesia, and alleviates the need for transport.

Visual confirmation in real-time

Beyond reduced anesthesia time, a camera in the operating room allows the surgeon to confirm the lesion of interest has been removed in real time. Certainly, a preoperative lymphoscintigraphy can help with mapping, but it cannot visually confirm the lesion’s removal. The Ergo allows confirmation of lesion removal or, in some cases, identification of lesions that were thought to be removed or hidden behind another. Visual representation is a fail-safe that ultimately improves surgical outcome.

In the past, some have equated portability with lower quality images, but the Digirad Ergo doesn’t trade one benefit for another. It delivers high-quality images that technologists say rival any static nuclear camera and its compact, portable design offers maximum clinical versatility.

Read the full article, Use of intraoperative nuclear imaging leads to decreased anesthesia time and real-time confirmation of lesion removal , at the Journal of Pediatric Surgery.

Move from HEU to LEU Nearing Completion in the United States

Posted on: 03.08.18

Technetium (Tc-99m), the decay product of molybdenum-99 (Mo-99), is an essential component in cardiac nuclear imaging. In the past, the primary source for this radioisotope was highly enriched uranium (HEU), but market dynamics and legislative action have changed that. The last five years have seen a sustained move to low-enriched uranium (LEU), and the United States is expected to be fully transitioned to LEU by the end of 2018.

The Call for Change

The American Medical Isotope Protection Act of 2011 was enacted to not only promote the domestic production of molybdenum-99, but to replace the role of HEU in the production of medical radioactive isotopes.

Uranium is considered highly enriched when the concentration of the U-235 isotope exceeds 20%. If the proportion of U-235 is less than 20%, it’s categorized as low enriched uranium (LEU).

In an effort to reduce the amount and potential misuse of HEU, the Department of Energy promoted an initiative to reduce the dependence on HEU in the United States. Reactors around the world responded and have been moving toward the conversion from HEU to a process that uses LEU.

What the Move from HEU to LEU Means for Nuclear Imaging

The final product, Tc-99m, remains exactly the same regardless of the source material. There is no difference in the quality or effectiveness – only the raw material processed by the radiopharmacy. Both LEU and HEU approaches result in the same isotope with equivalent performance.

Even though there have been changes in the production process, nuclear medicine providers will not be affected by the shift. The availability of isotopes sourced from LEU generators is steadily increasing as the conversion continues throughout 2018.

U.S. manufacturers who produce Technetium-99 generators, and supply the radiopharmaceutical industry, are in full support of the conversion and are establishing a steady supply of radioisotopes derived from LEU sources. Although some feared that the shift would increase isotope prices, it appears that much of the conversion costs have already been factored in, and no dramatic increases are expected.

Ultimately the move from HEU to LEU will result in a more stable market and reliable supply of Tc-99 which is positive for the entire industry.

Diversified Molybdenum-99 Production Easing Supply Concerns

Posted on: 02.22.18

In recent years, there’s been a heightened focus on the supply of Molybdenum-99, the radioisotope used in nuclear diagnostic imaging. Previous regulatory and capacity issues have caused shipment delays, but today the outlook for molybdenum-99 supply has never been stronger.

Reactors step up production

One unlikely catalyst for the turnaround has been the closing of Canada’s National Research Universal (NRU) reactor in Chalk River, Ont., in 2016. At its closing, Chalk River produced nearly 30% of the world’s supply of molybdenum-99. The nuclear medicine community feared that the shortfall would jeopardize the supply.

Not only did the remaining world reactors in Europe, South Africa, and Australia more than fill the deficit left behind by the closing of Chalk River, an additional three reactors have come online, which has further strengthened the radioactive isotope’s supply.

The more stable supply can also be attributed to diversification. With almost one-third of the world’s supply produced by Chalk River and another significant portion from the High Flux Reactor in the Netherlands, any prolonged breakdown of the remaining worldwide reactors would cause disruption on the supply chain. Now, with the supply diversified across many more reactors, one reactor’s supply issue is less likely to cause a global impact.

Radiopharmacies and diversification

Radiopharmacies are also working smarter and using diversification to their advantage. Maintaining multiple relationships among suppliers allows them to minimize any potential service disruptions. If one reactor source suffers an extended setback, a well-positioned radiopharmacy can leverage the diversity they’ve created in their supply chain to continue providing reliable service and delivery.

In order to hedge against the impact of one reactor’s shortage, it’s critical for nuclear medicine departments, cardiology practices, and other consumers of radiopharmaceuticals to make sure their radiopharmacy partner has a diversified supply chain.

Exclusivity with one supplier may offer the most advantageous pricing. However, diversification opens additional doors and allows you to sidestep a shortage without interruption. In the molybdenum-99 supply chain, each cog in the wheel must run smoothly. When one breaks, those providers who have diversified their sources will be able to adjust while others who have exclusive contracts may not.

If you’re negotiating a radiopharmacy contract, it’s also prudent to protect yourself with a serviceability guarantee. This performance clause will allow you to exit the contract if your supply needs cannot be filled due to lack of diversification.

The future of isotope production

Diversification has proven to help successfully and effectively manage the delicate supply and demand of molybdenum-99. But, as we move forward, the industry is also looking at domestic sources of production that would not only increase availability in the United States, but also alleviate the time and travel challenges that come with crossing international boundaries.

While the supply chain is strong and the industry is continually working to mitigate any potential supply challenges to customers and the marketplace as a whole, there’s always room for improvement. Pursuing domestic production, new methods and improved technologies are sure to positively impact the future of isotope production.

ASNC 2017 Year in Review by Raymond Russell

Posted on: 02.01.18

In 2018 ASNC will be celebrating their 25th anniversary. As the year began, ASNC’s 2017 President, Raymond Russell, wrote an excellent post to Members looking back at the achievements of 2017. Digirad values the role ASNC plays in Nuclear Cardiology, and we look forward to collaborating with ASNC in the new year. Here’s Dr. Russell’s post:


It is hard to believe that the year is over-it has gone by in a blink of the eye. However, during that eye blink, the members and staff of ASNC have done an incredible amount of work to support the appropriate use of nuclear cardiology that helps improve the care of our patients. I am proud to have been given the honor to represent ASNC as president and work alongside the talented and hard-working individuals that make up ASNC. I would like to share with you the many accomplishments we have achieved in 2017 and my hopes for a healthy, prosperous, and peaceful 2018 for all.

17: Sharing Knowledge with Referring Health Professionals

ASNC continues to be welcomed at forums across the United States where attendees are seeking knowledge and insight to optimize appropriate referrals for cardiovascular imaging to ensure that patients are neither over- or undertreated. At the 50th anniversary conference of the American Academy of Physician Assistants, ACP.17, ASNC launched the Refer Wisely program, hosted an event that drew more than 280 attendees and positioned its booth as a hub for discussion about primary care professionals’ understanding of relevant appropriate use criteria.

16: Making MIPS Manageable

ASNC continues addressing MACRA and the move toward value-based healthcare on multiple fronts. Society volunteers and staff are in constant communication with government officials, advocating for simple, streamlined policies that will actually serve to improve patient care and outcomes. ASNC is developing a suite of tools to ease the challenges imaging professionals will face as new policies are enacted. The ImageGuide Registry has emerged as an unbeatable tool for meeting MACRA’s Merit-based Incentive Payment System (MIPS) requirements and avoiding reimbursement penalties. Enrollment in ImageGuide – now designated by CMS as a Qualified Clinical Data Registry for the fourth consecutive year – gives facilities access to benchmark data that are invaluable for improving the program quality while fulfilling MIPS reporting obligations. ASNC members are invited to enroll their facilities in ImageGuide Registry at no cost. The complimentary webinar, “Fulfill MIPS Requirements with ImageGuide Registry” explains how it works.

15: ASNC Across the Globe

In 2017, ASNC continued to grow its international presence as ASNC co-sponsored educational programs at meetings in Canada, Japan, Mexico, Portugal, Saudi Arabia, and Spain. ASNC members were invited to present at meetings in Argentina, Austria, Brazil, Chile, China, Cuba, Mexico, and Spain. Almost 10% of the ASNC membership’s practice in 64 countries. ASNC and IAEA hosted its first webinar delivered entirely in Spanish “Elaboración de un informe de cardiología nuclear con SPECT o PET,” it featured Erick Alexanderson, MD, and Fernando Mut, MD. 125 physicians and scientists attended the session. ASNC-IAEA also held its first Arabic/English Webinar entitled “Nuclear Cardiology in the Arab World: Challenges and Opportunities”

14: ASNC Secures AUC Program Delay until 2020

ASNC led an advocacy effort composed of multiple physician stakeholder groups calling for indefinite delay of the AUC Program while its value and necessity were evaluated in the context of the Quality Payment Program (QPP). By delaying the program in the Final Rule, CMS is acknowledging that it agrees with commenters that the goals of the QPP are consistent with those of the AUC program. CMS has delayed the effective date of the Appropriate Use Criteria (AUC) Program to Jan. 1, 2020.

13: Achieving New Heights with ASNC Education

ASNC has received the highest level of recognition, Accreditation with Commendation, from the Accreditation Council for Continuing Medical Education (ACCME). Accreditation with Commendation is awarded to CME providers that demonstrate compliance in all aspects of accreditation requirements and for demonstrating exemplary engagement with the environment in support of physician learning and quality improvement. ASNC demonstrated compliance with all 22 of ACCME’s accreditation criteria through a system of reporting for each and all of its 35 to 45 CME activities hosted each year, including live programs, enduring materials, journal CME, manuscript CME review and online learning reaching an average of more than 6,000 physicians annually. ASNC thanks its leaders, Education Committee members and Chair Donna Polk, MD, MPH, FASNC, program directors, Journal of Nuclear Cardiology CME editor and editor in chief, and staff for ensuring excellence in the Society’s educational initiatives.

12: Boosting JNC’s Impact Factor

The impact factor for ASNC’s esteemed Journal of Nuclear Cardiology climbed to its highest point since it was founded 24 years ago, a full point above its 2015 score. JNC now ranks 17th out of 126 current journals, up from the 27th position, in the Radiology, Nuclear Medicine and Medical Imaging category. JNC also jumped several positions in the Cardiac & Cardiovascular Systems category, from 49th to 38th.

11: ASNC in the Heart of America

There were a number of firsts at ASNC2017. ASNC’s annual meeting was held in Kansas City, Mo. for the first time. Physicians from 58 developing countries were able to access select ASNC2017 sessions as part of a livestreaming initiative supported by the International Atomic Energy Agency (IAEA) and ASNC2017 welcomed several new speakers and the Mayor of Kansas City. MOC points were offered for the attending the live annual meeting and the live Board Prep Course for the first time. Focus for last year’s meeting was disease-based sessions and peer networking. Check out ASNC2017 photos. Save the Date for ASNC2018 in San Francisco, Sept. 6-9!

10: Announcing Category III Code for Myocardial Blood Flow

As 2017 drew to a close, ASNC was pleased to announce that a new category III CPT code for Absolute Quantitation of Myocardial Blood Flow in PET would go into effect on Jan. 1, 2018. The new code is 0482T – Absolute quantitation of myocardial blood flow, positron emission tomography, rest and stress. Category III codes are important tools that help to substantiate utilization and clinical efficacy.

9: Improving Imaging in Women

ASNC advanced its mission of optimizing cardiovascular outcomes with two new resources focused on female patients. The latest ASNC consensus statement, “Myocardial Perfusion Imaging in Women for the Evaluation of Stable Ischemic Heart Disease: State-of-the-Evidence and Clinical Recommendations,” outlines themes that support effective imaging in women and has been heralded as an important step toward precision medicine. ASNC also teamed up with MedPage Today to produce “Women with Suspected Ischemic Heart Disease: What Is the Best Diagnostic Approach?

8: Achieving a Better National Coverage Decision for Cardiac PET

ASNC led a multi-society advocacy effort to remove prerequisite language for cardiac PET coverage in a local coverage policy. ASNC successfully advocated that the local policy should be aligned with the less onerous national coverage policy.

7: Expanding Your Imaging Toolbox with ASNC Practice Points

ASNC members have access to a growing database of Practice Points and other resources designed to help medical professionals select the best tests for each patient. 2017 saw the addition of a new downloadable Practice Point that distills key take-aways from ASNC’s 2016 Stress Protocols and Tracers Guideline. The Practice Point offers a clear, concise outline of indications, action mechanisms, procedural guidance, contraindications and test limitations for exercise stress testing as well as pharmacologic stress testing with adenosine, dipyridamole, dobutamine and regadenoson.

6: Expanding the ImageGuide Registry to Include Echo

ASNC and the American Society of Echocardiography (ASE) announced at ASNC2017, a partnership to develop an ASE Echocardiography Module, ImageGuideEcho™. This new module will allow the registry to support both nuclear cardiology and echocardiography laboratories as well interpreting physicians, technologists and sonographers from both fields. ImageGuide’s Qualified Clinical Data Registry (QCDR) designation from the Centers for Medicare and Medicaid Services combined with these new echocardiography performance measures will increase the registry’s value as a tool for meeting Merit-based Incentive Payment System (MIPS) requirements.

5: Announcing $50K in Research Fellowship Funding

ASNC and the Institute for the Advancement of Nuclear Cardiology (IANC) are inviting early-career nuclear cardiology investigators to apply for $50,000 in research project funding. The IANC Research Fellowship Award was established in 2017 to encourage and support careers in nuclear cardiology research while growing the science of cardiac imaging and advancing the specialty. The competition is open to most trainees, including post-doctoral fellows and junior faculty who intend to pursue academic careers in nuclear cardiology research. Submit your application for a chance to win funding to support your research, or share this opportunity with your colleagues. Please note: All applications must be received at ASNC headquarters by Jan. 31, 2018.

4: Just Starting Out

CareerStarter, a quarterly publication provides helpful tips to physicians starting their careers from those of us who have weathered those early steps. The CareerStarter newsletter has several focus areas: “JumpStart”–articles on key career hurdles, including employment negotiations and contracts. “Tips for FITs” (advice from mid-career ASNC members to help those at earlier phases of their career), “Freebies & Deep Discounts” (current best deals for education, networking and career advancement in nuclear cardiology)

3: Seek and You Shall Find

Continuing to be a resource for young professionals in the field, the nuclear cardiology community now has a new career-advancement tool! The ASNC Career Center, launched this past Fall and is a comprehensive resource for job-seekers and employers. Users will find job postings and will be able to add their own resumes, making it easy for employers and nuclear cardiology professionals to forge connections. Organizations seeking quality candidates are invited to post positions-at the ASNC member discounted rate!

2: 4,300 and Counting

ASNC continued its upward trend of new and returning memberships, achieving its strategic goals and ensuring that cardiovascular patients receive optimal imaging care this year, especially with our early-career/Fellow-In-Training members. There were more than 650 new members who joined ASNC in 2017, making this year’s total number of memberships the highest it’s been in the last 5 years! Thanks to ASNC’s Membership Committee chaired by Randy Thompson, MD, FASNC, and to every one of ASNC’s 4,300+ members for joining in our effort to lead the field and support education, advocacy, quality and professional development. Become an ASNC member

1: ASNC turns 25!

With the arrival of 2018, ASNC marks 25 years of supporting the nuclear cardiology community – its patients, professionals, partners and friends. We’ve launched a year-long celebration of our silver anniversary, so stay tuned for special communications that will highlight past accomplishments, provide access to special resources and opportunities and test your ASNC knowledge!

Raymond Russell, MD, PhD, MASNC
2017 President, ASNC

Digirad — Revolutionary solid-state nuclear cardiology equipment and services.

Making Healthcare Convenient. As Needed. When Needed. Where Needed.